ВУЗ: Не указан
Категория: Не указан
Дисциплина: Не указана
Добавлен: 04.10.2020
Просмотров: 2487
Скачиваний: 11
116
Марихуана: мифы и факты
12. Commission of Inquiry into the Non%Medical Use of Drugs, Final Report, Ottawa: Information Canada
(1972); Werkgroep Verdovende Middelen, Background and Risks of Drug Use, The Hague: Staatsuitgeverij (1972);
Advisory Committee on Drug Dependence, Cannabis, London: H.M. Stationery Office (1968); Senate Standing
Committee on Social Welfare, Drug Problems in Australia—An Intoxicated Society?, Canberra: Australian
Commonwealth Government Printing Office (1977).
13.
Nahas G.G., Greenwood A.
«The First Report of the National Commission on Marihuana (1972): Signal of
Misunderstanding or Exercise in Ambiguity?», Bulletin of the New York Academy of Medicine 50: 55—75 (1974);
Nahas G.G.
Marihuana: Deceptive Weed, New York: Raven Press (1973).
14.
Nahas G.G.
Keep Off the Grass, New York: Reader’s Digest Press (1976).
15. Subcommittee Hearings to Investigate the Administration of the Internal Se-curity Act and Other Internal
Security Laws, Marihuana%Hashish Epidemic and Its Impact on United States Security, Washington, DC: U.S.
Government Printing Office (1974), p. xii.
16. Institute of Medicine, Marijuana and Health, Washington, DC: National Academy Press (1982); Report on
Cannabis Use, Toronto: Addiction Research Foundation (1982).
17.
Jones R.
«Clinical Pharmacology of Marijuana», paper presented at National Institute of Health, Workshop
on the Medical Utility of Marijuana, Bethesda, MD (19 February 1997).
18. National Commission (1972), см. № 7, p. 8.
19. Ministry of Health, Welfare and Sport, Drug Policy in the Netherlands: Continuity and Change, The Netherlands
(1995).
20. «Deglamorising Cannabis», Lancet 346: 1241 (1995).
2.
МАРИХУАНА КАК ЛЕКАРСТВО
1. Drug Enforcement Administration, Drug Legalization: Myths and Misconceptions, Washington, DC: U.S.
Department of Justice (1994), p. 49.
2.
Peterson R.E.
The Marijuana as Medicine Scam, Lansing, MI: Michigan Office of Drug Control Policy
(undated).
3.
Schwartz R.A., Voth E.A.
«Marijuana as Medicine: Making a Silk Purse Out of a Sow's Ear», Journal of
Addictive Diseases 14: 15—21 (1995).
4. Drug Watch International, By Any Modern Medical Standard, Marijuana is No Medicine, Omaha (undated).
5. Barry McCaffrey, Director of National Drug Control Policy, Office of National Drug Control Policy Press
Release, Washington, DC (15 November 1996).
6.
Chang A.E. et al.
«Delta%Nine%Tetrahydrocannabinol as an Antiemetic in Cancer Patients Receiving High%
Dose Methotrexate: A Prospective Randomised Evaluation», Annals of Internal Medicine 91: 819—24 (1979);
Lucas
V.S., Laszlo J.
«Delta%9%Tetrahydrocannabinol for Refractory Vomiting Induced by Cancer Chemotherapy», Journal
of the American Medical Association 243: 1241—43 (1980);
Orr L.E. et al.
«Antiemetic Effect of Tetrahydrocannabinol
Compared with Placebo and Prochlorperazine in Chemotherapy%Associated Nausea and Emesis», Archives of Internal
Medicine 140:1431—33 (1980);
Ekert K. et al.
«Amelioration of Cancer Chemotherapy Induced Nausea and Vomiting
by Delta%9%Tetrahydrocannabinol», Medical Journal of Australia 2:657—59 (1979);
Sallan S.E. et al.
«Antiemetic
Effect of Delta%9%Tetrahydrocannabinol in Patients Receiving Cancer Chemotherapy», New England Journal of Medicine
293: 795—97 (1975);
Sallan S.E. et al
. «Antiemetics in Patients Receiving Chemotherapy for Cancer: A Randomized
Comparison of Delta%9%Tetrahydrocannabinol and Prochlorperazine», New England Journal of Medicine 302: 135—
38 (1980);
Ungerleider J.T. et al.
«Cannabis and Cancer Chemotherapy: A Comparison of Oral Delta%9%THC and
Prochlorperazine», Cancer 50: 636—45 (1982);
Vinciguerra V. et al.
«Inhalation of Marijuana as an Antiemetic for
Cancer Chemotherapy», New York State Journal of Medicine 85: 525—27 (1988);
Frytak S. et al.
«Delta%9%
Tetrahydrocannabinol as an Antiemetic for Patients Receiving Cancer Chemotherapy: A Comparison with
Prochlorperazine and a Placebo», Annals of Internal Medicine 91: 825—30 (1979);
KluinNeleman J.C. et al.
«Delta%
9%Tetrahydrocannabinol (THC) as an Antiemetic in Patients Treated with Cancerchemotherapy: A Double%Blind Cross%
Over Trial Against Placebo», Veterinary and Human Toxicology 21: 338—40 (1979).
7.
Foltin R.W. et al.
«Behavioral Analysis of Marijuana Effects on Food Intake in Humans», Pharmacology
Biochemistry and Behavior 25: 577—82 (1986);
Foltin R.W. et al.
«Effects of Smoked Marijuana on Food Intake
and Body Weight of Humans Living in a Residential Laboratory», Appetite 11: 1—14 (1988);
Plasse T.F. et al.
«Recent Clinical Experience with Dronabinol» Pharmacology Biochemistry and Behavior 40: 695—700 (1991);
Regelson W. et al.
«Delta%9%Tetrahydrocannabinol as an Effective Antidepressant and Appetite%Stimulating Agent in
Advanced Cancer Patients», pp. 763—76 in Braude M.C., Szara S. (eds) The Pharmacology of Marihuana, New York:
117
Литература
Raven Press (1976);
Gorter R. et al.
«Dronabinol Effects on Weight in Patients with HIV Infection», AIDS 6: 127—
38 (1992);
Greenberg I. et al.
«Effects of Marijuana use on Body Weight and Caloric Intake in Humans»,
Psychopharmacology 49: 79—84 (1976);
Ungerleider J.T. et al.
(1979), см. № 6;
Ekert K. et al.
(1979), см. № 6;
Sallan S.E. et al.
(1980), см. № 6.
8.
Crawford W.J., Merritt J.C.
«Effect of Tetrahydrocannabinol on Arterial and Intraocular Hypertension»,
International Journal of Clinical Pharmacology and Biopharmaceutics 17: 191—96 (1979);
Merritt J.C. et al.
«Effects
of Marijuana on Intraocular and Blood Pressure in Glaucoma», Ophthalmology 87: 222—28 (1980);
Merritt J.C. et
al.
«Oral Delta%9%Tetrahydrocannabinol in Heterogeneous Glaucoma», Annals of Ophthalmology 12: 947—50 (1980);
Hepler R.S., Petrus R.
«Experiences with Administration of Marijuana to Glaucoma Patients», pp. 63—76 in Cohen
S., Stillman R. (eds), The Therapeutic Potential of Marihuana, New York: Plenum Medical Book Company (1976);
Hepler R.S. et al.
«Ocular Effects of Marijuana Smoking», pp. 815—24 in Braude M.C., Szara S. (eds), Pharmacology
of Marihuana, New York: Raven Press (1976).
9.
Malec J. et al.
«Cannabis Effect on Spasticity in Spinal Cord Injury», Archives of Physical and Medical
Rehabilitation 63: 116—18 (1982);
Dunn M., Davis R.
«The Perceived Effects of Marijuana on Spinal Cord Injured
Males » Paraplegia 12: 175 (1974);
Mauer M. et al.
«Delta%9%Tetrahydrocannibinol Shows Antispastic and Analgesic
Effects in a Single Case Double%Blind Trial», European Archives of Psychiatry and Clinical Neuroscience 240: 1—
4 (1990);
Hanigan W.C. et al.
«The Effect of Delta%9%THC on Human Spasticity», Clinical Pharmacology and
Therapeutics 39: 198 (1986).
10.
Ungerleider J.T. et al.
«Delta%9%THC in the Treatment of Spasticity Associated with Multiple Sclerosis»
Advances in Alcohol and Substance Abuse 7: 39—50 (1987);
Petro D.J.
«Marijuana as a Therapeutic Agent for Muscle
Spasm or Spasricity» Psychosomatics 21: 81—85 (1980);
Petro D.J., Ellenberger C.
«Treatment of Human Spasticity
with Delta%9%Tetrahydrocannabinol», Journal of Clinical Pharmacology 21: 413—165 (1981);
Meinck H.M. et al.
«Effect of Cannabinoids on Spasticity and Ataxia in Multiple Sclerosis», Journal of Neurology 236: 120—22 (1989);
Consroe P. et al.
«The Perceived Effects of Cannabis Smoking in Patients with Multiple Sclerosis», paper presented
at the annual meeting of the International Cannabinoid Research Society (June 1996).
11.
Clifford D.B.
«Tetrahydrocannabinol for Tremor in Multiple Sclerosis», Annals of Neurology 13: 669—71
(1983).
12.
Grinspoon L., Bakalar J.B.
Marihuana: The Forbidden Medicine, Revised and Expanded Edition, New
Haven: Yale University Press (1997);
Pertwee R.G.
«Pharmacological, Physiological and Clinical Implications of the
Discovery of Cannabinoid Receptors: An Overview», pp. 1—34 in Pertwee R.G. (ed), Cannabinoid Receptors, New
York: Academic Press (1995);
Consroe P.P., Wood G.C.
«Anticonvulsant Nature of Marijuana Smoking» Journal of
the American Medical Association 243: 306—7 (1975);
Noyes R., Baram D.A.
«Cannabis Analgesia», Comprehensive
Psychiatry 15: 531—35 (1974).
13.
Cunha. J.M. et al.
«Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic Patients»,
Pharmacology 21: 175—85 (1980);
Consroe P. P., Snider S.R.
«Therapeutic Potential of Cannabinoids in Neurological
Disorders», pp. 21—50 in Mechoulam R. (ed), Cannabinoids as Therapeutic Agents, Boca Raton: CRC Press (1986).
14. Uniform Controlled Substances Act of 1970, 21 U.S. Sec. 800.
15. «MPP Analyzes States' Medicinal Marijuana Laws», Marijuana Policy Report 2, 3: 1—6 (1996).
16.
Wren C.S.
«Votes on Marijuana Are Stirring Debate», New York Times (17 November 1996), p. 16.
17.
Cotton P.
«Government Extinguishes Marijuana Access, Advocates Smell Politics» Journal of the American
Medical Association 267: 2573—74 (1992);
Doblin R.
«Reflections on Strategies for Psychedelic Research in Light
of the Medical Marijuana Struggle», Newsletter of the Multidisciplinary Association for Psychedelic Studies 3, 2: 6—
7 (1992).
18.
Randall R.
«How Cancer and AIDS Patients Suffer at the Hands of the DEA», pp. 104—6 in Trebach A.S.,
Zeese K.B. (eds), Drug Prohibition and the Conscience of Nations, Washington, DC: The Drug Policy Foundation
(1990);
Treaster J.B.
«Healing Herb or Narcotic? Marijuana as Medication » New York Times (14 November 1993),
p. 37;
Meyer E.L.
«Marijuana as Medicine at Heart of Md. Case», Washington Post (20 December 1994), p. Dl;
Goldin D.
«Marijuana Cure: Rx for Arrest», New York Times (10 September 1995), p. CY8; «Prohibition of Marijuana
Prescribing Will Be Tested in Ohio», New York Times (17 September 1995), p. 29.
19.
Agurell S. et al.
«Pharmacokinetics and Metabolism of Delta%1%Tetrahydrocannabinol and Other Cannabinoids
with Emphasis on Man», Pharmacological Reviews 38: 21—43 (1986);
Lemberger L. et al.
«Delta%9%
Tetrahydrocannabinol: Temporal Correlation of the Psychologic Effects and Blood Levels After Various Routes of
Administration», New England Journal of Medicine 268: 685—88 (1972);
PerezReyes M. et al.
«The Clinical
Pharmacology and Dynamics of Marijuana Cigarette Smoking» Journal of Clinical Pharmacology 21: 201—75 (1981);
118
Марихуана: мифы и факты
Wall M.E., PerezReyes M.
«The Metabolism of Delta%9%Tetrahydrocannabinol and Related Cannabinoids in Man»,
Journal of Clinical Pharmacology 21: 178—895 (1981);
Ohlsson A. et al.
«Plasma Delta%9%THC Concentrations and
Clinical Effects After Oral and Intravenous Administration and Smoking» Clinical Pharmacology and Therapeutics 28:
409—16 (1980);
Mason A.P., McBay A.J.
«Cannabis: Pharmacology and Interpretation of Effects», Journal of
Forensic Sciences 30: 615—31 (1985).
20.
Mattes R.D. et al.
«Cannabinoids and Appetite Stimulation» Pharmacology Biochemistry and Behavior 49:
187—95 (1994);
Peat M.A.
«Distribution of Delta%9%Tetrahydrocannabinol and Its Metabolites», Advances in
Analytical Toxicology 2: 186—217 (1989);
Wall M.E. et al.
«Metabolism, Disposition, and Kinetics of Delta%9%
Tetrahydrocannabinol in Men and Women», Clinical Pharmacology and Therapeutics 34: 352—63 (1983);
Agurell
S. et al.
(1986), см. № 19.
21.
Mattes R.D. et al.
«Bypassing the First%Pass Effect for the Therapeutic Use of Cannabinoids» Pharmacology
Biochemistry and Behavior 44: 745—47 (1993).
22.
Mattes R.D. et al.
(1994), см. № 20;
Agurell S. et al.
(1986), см. № 19;
Wall M.E., PerezReyes M.
(1981), см. № 19.
23.
Hollister L.E. et al.
«Do Plasma Concentrations of Delta%9%Tetrahydrocannabinol Reflect the Degree of
Intoxication?», Journal of Clinical Pharmacology 21: 171—775 (1981);
Chait L.D., Zacny J.P.
«Reinforcing and
Subjective Effects of Oral Delta%9%THC and Smoked Marijuana in Humans», Psychopharmacology 107: 255—62
(1992);
Ohlsson A. et al.
(1980), см. № 19;
Peat M.A.
(1989), см. № 20;
Lemberger Z. et al.
(1972), см. № 19.
24.
Cone E.J. et al.
«Marijuana%Laced Brownies: Behavioral Effects, Physiological Effects, and Urinalysis in
Humans Following Ingesrion», Journal of Analytical Toxicology 12: 169—75 (1988);
Lemberger Z. et al.
(1972), см.
№ 19;
Chait Z.D., Zacny Z.P.
(1992), см. № 23;
Ohlsson A. et al.
(1980), см. № 19.
25.
PerezReyes M.
«Pharmacodynamics of Certain Drugs of Abuse», pp. 287—310 in Barnett G., Chiang C.N.
(eds), Pharmacokinetics and Pharmacodynamics of Psychoactive Drugs, Foster City, CA: Biomedical Publications
(1985);
Sallan S.E. et al.
(1975), см. № 6;
Chait Z.D., Zacny Z.P.
(1992), см. № 23.
26.
PerezReyes M. et al.
«Intravenous Injection in Man of Delta%9%Tetrahydrocannabinol and ll%Hydroxy%
Delta%9%Tetrahydrocannabinol», Science 177: 633—35 (1972);
PerezReyes M. et al.
«A Comparison of the
Pharmacological Activity of Delta%9%Tetrahydrocannabinol and Its Monohydroxylated Metabolites in Man» Experientia
29: 1009—10 (1973);
Lemberger L. et al.
«Comparative Pharmacology of Delta%9%Tetrahydrocannabinol and its
Metabolite 11%OH%Delta%9%THC», Journal of Clinical Investigation 54: 2411—17 (1973);
Wall M.E., PerezReyes
M.
(1981), см. № 19;
Agurell S. et al.
(1986), см. № 19.
27.
Mason A.P., McBay A.Z.
(1985), см. № 19;
Agurell S. et al.
(1986), см. № 19;
Lemberger M. et al.
(1973), см. № 26;
PerezReyes et al.
(1973), см. № 26.
28.
Mason A.P. McBay A.Z.
(1985), см. № 19;
Agurell S. et al.
(1986), см. № 19;
Peat M.A.
(1989), см. №
20;
Ohlsson A. et al.
(1980), см. № 19.
29.
Karniol G. et al.
«Cannabidiol Interferes with the Effects of Delta%9%Tetrahydrocannabinol in Man», European
Journal of Pharmacology 28: 172—77 (1974);
Zuardi A.W. et al.
«Action of Cannabidiol on the Anxiety and Other
Effects Produced by Delta%9%THC in Normal Subjects», Psychopharmacology 76: 245—50 (1982).
30.
Frytak T.S. et al.
(1979), см. № 6.
31.
Schwartz R.H., Beveridge R.A.
«Marijuana as an Antiemetic Drug: How Useful Today? Opinions From
Clinical Oncologists», Journal of Addictive Diseases 13: 53—65 (1994).
32.
Schwartz R.H. et al.
«Marijuana to Prevent Nausea and Vomiting in Cancer Patients: A Survey of Clinical
Oncologists», Southern Medical Journal 90: 167—72 (1997).
33.
Doblin R., Kleiman M.A.R.
«Marijuana as an Anti%Emetic Medicine: A Survey of Oncologists' Attitudes and
Experiences», Journal of Clinical Oncology 19: 1275—1290 (1991).
34.
Schwartz R.H. et al.
(1997), см. № 32.
35.
Agurell S. et al.
(1986), см. № 19;
Ohlsson A. et al.
(1980), см. № 19.
36.
Elsohly M.A. et al.
«Rectal Bioavailablity of Delta%9%Tetrahydrocannabinol From Various Esters»,
Pharmacology Biochemistry and Behavior 40: 497—502 (1991);
Mattes R.D. et al.
(1993), см. № 21.
37.
Olsen J.L. et al.
«An Inhalation Aerosol of Delta%9%Tetrahydrocannabinol», Journal of Pharmacy and
Pharmacology 28: 86 (1976).
38. National Commission on Marihuana and Drug Abuse, Marihuana: A Signal of Misunderstanding, Washington,
D.C: U.S. Government Printing Office (1972);
Cohen S.
«Therapeutic Aspects», pp. 194—225 in Petersen R.C. (ed),
119
Литература
Marihuana Research Findings: 1976, Rockville, MD: National Institute on Drug Abuse (1977);
Cohen S., Stillman
R.C.
(eds), The Therapeutic Potential of Marihuana, New York: Plenum Medical Book Company (1976); National
Institute on Drug Abuse, Marijuana and Healtb, Eighth Annual Report to the U.S. Congress from the Secretary of
Health and Human Services (1980).
39. «Access to Cannabinoids and Marijuana for Research and Treatment», Appendix III, pp. 175—76 in Mechoulam
R. (ed), Cannabinoids as Therapeutic Agents, Boca Raton, FL: CRC Press (1986).
40.
Randall R.C.
(ed), Marijuana, Medicine and the Law, Washington, DC: Galen Press (1988), pp. 27—50.
41. National Institute on Drug Abuse, Marihuana and Health, Sixth Annual Report to the U.S. Congress from
the Secretary of Health, Education and Welfare (1976).
42. National Institute on Drug Abuse, Marihuana and Health, Seventh Annual Report to the U.S. Congress from
the Secretary of Health, Education and Welfare (1977); National Institute on Drug Abuse (1980), см. № 37.
43. Drug Policy Office, Federal Strategy for Prevention of Drug Abuse and Drug Trafficking, Washington, DC:
The White House (1982).
44. National Institute on Drug Abuse, Marijuana and Health, Ninth Report to the U.S. Congress from the
Secretary of Health and Human Services (1982), p. 5.
45. 54 Federal Register 53767 (29 December 1989).
46. In the Matter of Marijuana Rescheduling, Docket 86—22, Opinion, Recommended Ruling, Findings of Fact,
Conclusions of Law, and Decision of Administrative Law Judge. Washington, DC: Drug Enforcement Administration
(6 September 1988).
47. Alliance for Cannabis Therapeutics and NORML v DEA, 15 F.2d 1131 (D.C. Cir. 1994).
48. 57 Federal Register 10499 (26 March 1992).
49.
Cotton P.
(1992), см. № 17; «U.S. Rescinds Approval of Marijuana as Therapy», New York Times (11 March
1992), p. A21.
50.
Voelker R.
«Medical Marijuana: A Trial of Science and Politics» Journal of the American Medical Association
271: 1645 (1994).
51. Drug Enforcement Administration Press Release, «Response to JAMA Article Titled «Marihuana as Medicine»,
Washington, DC (20 June 1995).
52. Drug Enforcement Administration (1994), см. № 1.
53.
Doblin R.
«Medical Marijuana Research: NIDA Just Says No to Science», Newsletter of the Multidisciplinary
Association for Psychedelic Studies 5, 4: 11—13 (1995);
Lehrman S.
«U.S. Drug Agencies Resist Medicinal%Pot
Plan», San Francisco Examiner (8 January 1995), p. B2;
Okie S.
«Plan to Test Drug's Effectiveness in Bureaucratic
Limbo», Washington Post Health (19 November 1996), p. 7.
54.
McCaffrey B.
Director of National Drug Control Policy, Senate Judiciary Committee Hearings, Teenage
Drug Use (4 September 1996).
55. Office of National Drug Control Policy, The Administration's Response to the Passage of California Proposition
215 and Arisona Proposition 200, Washington, DC (30 December 1996); «Doctors Given Federal Threat on Marijuana:
U.S. Acts to Overcome States' Easing of Law», New York Times (31 December 1996), p. 1.
56.
Lapey J.
The Medical Marijuana Scam, Hanover, MA: Concerned Citizens for Drug Prevention, Inc. (1993);
Bennett S.S.
Therapeutic Marijuana: Fact or Fiction, Portland: Oregon Federation of Parents for Drug Free Youth
(1992);
Voth E.A.
The International Drug Strategy Institute Position Paper on the Medicinal Applications of Marijuana,
Drug Watch International, Omaha (no date);
Gorman T.J.
Marijuana is NOT a Medicine, Santa Clarita, CA: California
Narcotics Officers' Association (1996); Center on Addiction and Substance Abuse Press Release, «Majority of
Californians Support Marijuana for Terminally Ill But Reject Other Provisions», New York (28 October 1996).
57.
Gwynne P.
«Trials of Medical Marijuana's Medical Potential Languish as Government Says Just Say No»,
The Scientist 9, 23: 1—2 (1995).
58. American Public Health Association, Access to Therapeutic Marijuana / Cannabis, Resolution 9513 (1995).
59. Federation of American Scientists, Medical Use of Whole Cannabis (1994).
60. See Alliance for Cannabis Therapeutics and NORML v DEA, 15 F.2d 1131 (D.C. Cir. 1994).
61. «Choice for Surgeon General Favors Medicinal Marijuana Use», Washington Post (20 December 1992), p. A16.
62. Therapeutic Use of Marijuana, Resolution of the National Association of Attorneys General (25 June 1983).
63. Resolution Calling for the Reclassification of Marijuana to Schedule II of the Controlled Substances Act,
National Association of Criminal Defense Lawyers (May 1987).
120
Марихуана: мифы и факты
64.
Kassirer J.R.
«Federal Foolishness and Marijuana», New England Journal of Medicine 336: 366—67 (1997).
65.
Grinspoon L., Bakalar J.B.
«Marihuana as Medicine: A Plea for Reconsideration», Journal of the American
Medical Association 273: 1875—76 (1995).
66. «A Medical Opinion on Marijuana», New York Times (31 January 1997); «Lift the Ban on Using Marijuana
for Medicine», USA Today (11 January 1994); «Out%of%Touch Marijuana Ban Ill Serves Patients», USA Today (2
January 1997); «Reducing the Drug War to Absurdity» Chicago Tribune (11 July 1995); «Giving Suffering Patients
a Break», The Oakland Tribune (19 January 1994); «Medicinal Marijuana», The Oakland Tribune (20 June 1995); «Try
Some Mercy», San Jose Mercury News (10 January 1994); «Let's OK Pot as Medicine», The Capital Times, Madison,
Wisconsin (27 September 1993); «Let Doctors Prescribe Pot», Albany Times Union (4 January 1993); «Medical Use
of Marijuana: Let Doctors Decide», The Star Tribune, Minneapolis (23 March 1992).
67.
Beldon, Russonello
«American Voters' Opinions on the Use and Legalization of Marijuana», national random
poll conducted for the American Civil Liberties Union, New York (1995); The Field Institute, poll of California voters'
support for Proposition 215 (1996); Center on Addiction and Substance Abuse (1996), см. № 56; Lake Research, Inc.
national random poll conducted for the Lindesmith Center, New York (1997).
68.
Hearn W.
«Considering Cannabis», American Medical News 38, 37: 11—13 (1995);
Wren C.S.
«Doctors
Criticize Move Against State Measures», New York Times (31 December 1996), p. D18;
Goodavage M.
«Calif, to
Vote on Legalizing Pot as Medicine», USA Today (16 July 1996), p. 10A;
Rogers P.
«Pot Charges Against Epileptic
Dismissed: Santa Cruz Woman Had Faced Prison Term», San Jose Mercury News (27 March 1993), p. B5.
69.
Wesner B.
«The Medical Marijuana Issue Among PWAs: Reports of Therapeutic Use and Attitudes Toward
Legal Reform», Working Paper, Honolulu: University of Hawaii (1996).
70.
Marin G.
«State Pot Order Rejected: S.F. Sheriff Won't Enforce Ban on Club's Sale», San Francisco Chronicle
(7 August 1996); «Rx to Peddle Pot? Police Say No», Kentucky Post (27 February 1996), p. 1;
German P.
«Cannabis
Provider: Interview with Steven Smith», High Times: 5 (April 1994);
Peacock L.
«Doctors or Dope Dealers?»,
Arkansas Times (16 December 1993), p. 17;
Treaster J.
«Healing Herb or Narcotic? Marijuana as Medicine», New
York Times (14 November 1993), p. 37;
Murphy K.
«Arrest Sounds an Alarm for Medicinal Marijuana Clubs», Los
Angeles Times (14 June 1995);
Goldberg C.
«Marijuana Club Helps Those in Pain», New York Times (25 February
1996), p. 16;
Fisher I.
«The Marijuana Club», New York Times (10 January 1997), p. B1.
71. Food, Drugs, and Cosmetics Act, Section 505 (d) (7).
72.
Pertwee R.G.
(1995), см. № 12.
73.
Dansak D.
«In the Matter of Marijuana Rescheduling Petition», affidavit filed in Drug Enforcement
Administration Hearing, Docket 86—22 (1987), pp. 149—58 in Randall R.C. (ed), Cancer Treatment and Marijuana,
Washington, DC: Galen Press (1990);
Vinciguerra V. et al.
(1988), см. № 6;
Chang A.E. et al.
(1979), см. № 6;
Hepler R.S., Petrus R.
(1976), см. № 8.
74.
Gingrich N.
«Legal Status of Marijuana», Journal of the American Medical Association 247: 1563 (1982).
3.
МАРИХУАНА И НАРКОМАНИЯ
1. National Institute on Drug Abuse, «Marijuana Treatments Involving Social Support or Relapse Prevention
Appear to Reduce Chronic Drug Use», NIDA Nоtes 5, 2 (1990), p. 16.
2.
Shalala D.E.
Secretary of Health and Human Services, «Say 'No' to Legalization of Marijuana», Wall Street
Journal (18 August 1995), p. A10.
3.
Swan N.
«A Look at Marijuana's Harmful Effects», NIDA Notes 9, 2 (1994) p. 16.
4. National Institute on Drug Abuse, Marijuana: What Parents Need to Know, Rockville, MD (1995), p. 19.
5.
Johnston L.D. et al.
National Survey Results on Drug Use from the Monitoring the Future Study, 1975—
1994, Volume II: College Students and Young Adults, Rockville, MD: U.S. Department of Health and Human
Services (1996), p. 43.
6. Substance Abuse and Mental Health Services Administration, National Household Survey on Drug Abuse:
Population Estimates 1994, Rockville, MD: U.S. Department of Health and Human Services (1995).
7.
Grinspoon L.
Marihuana Reconsidered, Cambridge, MA: Harvard University Press (1971);
Grinspoon L.,
Bakalar J.B.
Marijuana: The Forbidden Medicine, New Haven: Yale University Press (1993);
Sloman L.
Reefer
Madness: Marijuana in America, New York: Grove Press (1979);
Novak W.
High Culture: Marijuana in the Lives of
Americans, The Cannabis Institute of America, Inc. (1980).
8.
Kandel D.B., Davies M.
«Progression to Regular Marijuana Involvement: Phenomenology and Risk Factors
for Near Daily Users», pp. 211—54 in Glanzt M. Pickens R. (eds), Vulnerability to Drug Abuse, Washington, DC:
American Psychological Association (1992).